Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
Noortje VerschoorManouk K BosIngeborg E de KruijffMai N VanJaco KraanJan C DroogerJohanna M ZuetenhorstSaskia M WiltingStefan SleijferAgnes JagerJohn W M MartensPublished in: Breast cancer research and treatment (2024)
No clinical benefit of trastuzumab was observed, although this study was performed in a limited number of patients. Additionally, we observed a strong correlation between the number of evaluable CTCs and the presence of HER2-positive CTCs. We argue that randomized studies investigating agents that are proven to be solely effective in the HER2-positive patient group in patients with HER2-positive CTCs and HER2-negative tissue are currently infeasible. Several factors contribute to this impracticality, including the need for more stringent thresholds, and the rapidly evolving landscape of cancer treatments.
Keyphrases
- circulating tumor cells
- metastatic breast cancer
- end stage renal disease
- circulating tumor
- chronic kidney disease
- open label
- epidermal growth factor receptor
- newly diagnosed
- ejection fraction
- double blind
- case report
- placebo controlled
- squamous cell carcinoma
- clinical trial
- prognostic factors
- papillary thyroid
- locally advanced
- patient reported